235 related articles for article (PubMed ID: 31264983)
1. Incidence of osteonecrosis of the jaw by the use of osteoclast inhibitors in patients with bone metastases: a retrospective cohort study.
Chaurand-Lara J; Pacheco-Ruiz L; Trejo-Campos JL; Facio-Umaña JA; Mora-Pérez J
Cir Cir; 2019; 87(4):396-401. PubMed ID: 31264983
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
[TBL] [Abstract][Full Text] [Related]
3. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
[TBL] [Abstract][Full Text] [Related]
4. Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden.
Ehrenstein V; Heide-Jørgensen U; Schiødt M; Akre O; Herlofson BB; Hansen S; Larsson Wexell C; Nørholt SE; Tretli S; Kjellman A; Glennane A; Lowe KA; Sørensen HT
Cancer; 2021 Nov; 127(21):4050-4058. PubMed ID: 34310704
[TBL] [Abstract][Full Text] [Related]
5. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
[TBL] [Abstract][Full Text] [Related]
6. Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Analysis of the French Pharmacovigilance Database.
Amigues C; Fresse A; Roux CH; Gauthier S; Vieillard MH; Drici MD; Breuil V;
Joint Bone Spine; 2023 Dec; 90(6):105599. PubMed ID: 37271278
[TBL] [Abstract][Full Text] [Related]
7. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
8. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.
Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
Support Care Cancer; 2022 Mar; 30(3):2341-2348. PubMed ID: 34738163
[TBL] [Abstract][Full Text] [Related]
9. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
Fusco V; Campisi G; Bedogni A
Support Care Cancer; 2022 Sep; 30(9):7047-7051. PubMed ID: 35312858
[TBL] [Abstract][Full Text] [Related]
10. Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan.
Liu FC; Luk KC; Chen YC
Osteoporos Int; 2023 Oct; 34(10):1729-1737. PubMed ID: 37326685
[TBL] [Abstract][Full Text] [Related]
11. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
Cancer Chemother Pharmacol; 2021 Jun; 87(6):871-877. PubMed ID: 33791853
[TBL] [Abstract][Full Text] [Related]
12. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
Sidhu HK
Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
[TBL] [Abstract][Full Text] [Related]
13. A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab.
Bracchi P; Zecca E; Brunelli C; Miceli R; Tinè G; Maniezzo M; Lo Dico S; Caputo M; Shkodra M; Caraceni AT
Cancer Med; 2023 Sep; 12(17):18317-18326. PubMed ID: 37559413
[TBL] [Abstract][Full Text] [Related]
14. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
15. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.
Saad F; Brown JE; Van Poznak C; Ibrahim T; Stemmer SM; Stopeck AT; Diel IJ; Takahashi S; Shore N; Henry DH; Barrios CH; Facon T; Senecal F; Fizazi K; Zhou L; Daniels A; Carrière P; Dansey R
Ann Oncol; 2012 May; 23(5):1341-1347. PubMed ID: 21986094
[TBL] [Abstract][Full Text] [Related]
16. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.
Khan AA; Morrison A; Kendler DL; Rizzoli R; Hanley DA; Felsenberg D; McCauley LK; O'Ryan F; Reid IR; Ruggiero SL; Taguchi A; Tetradis S; Watts NB; Brandi ML; Peters E; Guise T; Eastell R; Cheung AM; Morin SN; Masri B; Cooper C; Morgan SL; Obermayer-Pietsch B; Langdahl BL; Dabagh RA; Davison KS; Sándor GK; Josse RG; Bhandari M; El Rabbany M; Pierroz DD; Sulimani R; Saunders DP; Brown JP; Compston J;
J Clin Densitom; 2017; 20(1):8-24. PubMed ID: 27956123
[TBL] [Abstract][Full Text] [Related]
17. Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw.
Higuchi T; Soga Y; Muro M; Kajizono M; Kitamura Y; Sendo T; Sasaki A
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jun; 125(6):547-551. PubMed ID: 29574058
[TBL] [Abstract][Full Text] [Related]
18. Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis.
Bagan J; Peydró A; Calvo J; Leopoldo M; Jiménez Y; Bagan L
Oral Dis; 2016 May; 22(4):324-9. PubMed ID: 26818808
[TBL] [Abstract][Full Text] [Related]
19. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
Kajizono M; Sada H; Sugiura Y; Soga Y; Kitamura Y; Matsuoka J; Sendo T
Biol Pharm Bull; 2015; 38(12):1850-5. PubMed ID: 26632176
[TBL] [Abstract][Full Text] [Related]
20. Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis.
Everts-Graber J; Lehmann D; Burkard JP; Schaller B; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
J Bone Miner Res; 2022 Feb; 37(2):340-348. PubMed ID: 34787342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
